MBC

Shimmer by Cindy Launches New Jewelry Collection for Metastatic Breast Cancer (MBC) Awareness in Partnership with METAvivor

Retrieved on: 
Friday, August 18, 2023
Collection, Partnership, Timeless, Face, Breast Cancer Awareness Month, Cure, MBC, Breast cancer, Jewellery, Research, Memory, Shimmer

CHICAGO, Aug. 18, 2023 /PRNewswire-PRWeb/ -- Shimmer by Cindy, the jewelry brand known for its unique signature and charitable collections including "Timeless" and" Shimmer for the Cure", today launches a new Shimmer for the Cure - MBC Collection with 100% of proceeds going to METAvivor, a non-profit raising awareness and support for stage 4, metastatic breast cancer (MBC).

Key Points: 
  • 100% of Profits from Shimmer by Cindy, Shimmer for the Cure MBC Collection to be Donated to METAvivor for MBC Research
    CHICAGO, Aug. 18, 2023 /PRNewswire-PRWeb/ -- Shimmer by Cindy, the jewelry brand known for its unique signature and charitable collections including "Timeless" and" Shimmer for the Cure", today launches a new Shimmer for the Cure - MBC Collection with 100% of proceeds going to METAvivor, a non-profit raising awareness and support for stage 4, metastatic breast cancer (MBC).
  • The jewelry pieces included are a variety of different rings, bracelets, necklaces, and earrings set in brass with rhodium plating embellished with teal, pink, and green cubic zirconia which make up the tri-color metastatic breast cancer (MBC) ribbon.
  • Liz Ferenciak, Addante's daughter and the face of this collection, sparked this partnership by introducing Shimmer by Cindy and METAvivor.
  • This collection launches leading up to October, which is acknowledged as Breast Cancer Awareness month.

MasterBrand Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Home Goods, Construction & Property, Other Manufacturing, Other Construction & Property, Interior Design, Manufacturing, Retail, Residential Building & Real Estate, Insurance, Tax, GAAP, Forecasting, Security, Public expenditure, EBITDA, Investment, MBC, Webcast, Depreciation, NYSE, Fortune Brands Home & Security, Video game, Bank, Textile, Bookkeeping

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced second quarter 2023 financial results.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced second quarter 2023 financial results.
  • “The team’s continued execution on our three key strategic initiatives, and our disciplined use of The MasterBrand Way, drove our strong results in the second quarter.
  • Gross profit margin expanded 481 basis points to 34.0%, compared to 29.2% in the second quarter of 2022.
  • Net income was $51.2 million, compared to $40.9 million in the second quarter of 2022, primarily due to an asset impairment charge of $26.0 million in the second quarter of last year, partially offset by higher interest expense of $17.2 million in the second quarter of 2023, related to bank debt issued in December 2022 at the time of the separation from Fortune Brands Home and Security.

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Retrieved on: 
Friday, July 21, 2023
Medicine, Neoplasm, European Medicines Agency, Diarrhea, Arthralgia, Doctor of Philosophy, Committee, IRCCS, MD, Patient, Division, Risk, European, Committee for Medicinal Products for Human Use, AST, University of Milano-Bicocca, Fatigue, University, Cholesterol, Constipation, Bone pain, EMA, Vomiting, Back pain, HIV disease progression rates, ALT, Headache, Death, Elacestrant, Civil service commission, Creatinine, Triglyceride, CDK, MBC, Indigestion, SOC, Abdominal pain, PFS, European Institute of Oncology, Menarini, European Commission, CHMP, Thrombosis, Progression-free survival, Anemia, ESR1, Advanced Therapy Medicinal Product, Woman, Periodic breathing, European Institute, Drug development, Nausea, Potassium, ER, Breast cancer, Medical imaging, Pharmaceutical industry, EU

ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.

Key Points: 
  • ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.
  • "Patients living with metastatic breast cancer are in need of efficacious and tolerable treatment options.
  • ORSERDU, if approved, will also provide a convenient daily oral treatment," said Elcin Barker Ergun, CEO of the Menarini Group.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Retrieved on: 
Friday, July 21, 2023
Medicine, Neoplasm, European Medicines Agency, Diarrhea, Arthralgia, Doctor of Philosophy, Committee, IRCCS, MD, Patient, Division, Risk, European, Committee for Medicinal Products for Human Use, AST, University of Milano-Bicocca, Fatigue, University, Cholesterol, Constipation, Bone pain, EMA, Vomiting, Back pain, HIV disease progression rates, ALT, Headache, Death, Elacestrant, Civil service commission, Creatinine, Triglyceride, CDK, MBC, Indigestion, SOC, Abdominal pain, PFS, European Institute of Oncology, Menarini, European Commission, CHMP, Thrombosis, Progression-free survival, Anemia, ESR1, Advanced Therapy Medicinal Product, Woman, Periodic breathing, European Institute, Drug development, Nausea, Potassium, ER, Breast cancer, Medical imaging, Pharmaceutical industry, EU

ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.

Key Points: 
  • ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.
  • "Patients living with metastatic breast cancer are in need of efficacious and tolerable treatment options.
  • ORSERDU, if approved, will also provide a convenient daily oral treatment," said Elcin Barker Ergun, CEO of the Menarini Group.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Retrieved on: 
Friday, July 21, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Thrombosis, University, Civil service commission, Progression-free survival, Creatinine, Anemia, Triglyceride, ESR1, Neoplasm, CDK, Cholesterol, European Medicines Agency, MBC, Indigestion, Committee for Medicinal Products for Human Use, Constipation, Woman, Mutation, Periodic breathing, Multimedia, SOC, Doctor of Philosophy, Arthralgia, PFS, Diarrhea, Abdominal pain, Bone pain, Committee, EMA, Vomiting, European Institute, Back pain, European Institute of Oncology, IRCCS, HIV disease progression rates, MD, Patient, Division, Risk, European, Drug development, Nausea, ALT, Headache, CHMP, AST, Death, Potassium, University of Milano-Bicocca, European Commission, ER, Fatigue, Pharmaceutical industry, EU

ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.

Key Points: 
  • ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.
  • “Patients living with metastatic breast cancer are in need of efficacious and tolerable treatment options.
  • ORSERDU, if approved, will also provide a convenient daily oral treatment,” said Elcin Barker Ergun, CEO of the Menarini Group.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

MasterBrand to Announce Second Quarter 2023 Results on August 8

Retrieved on: 
Tuesday, July 11, 2023
Interior Design, Retail, Home Goods, Residential Building & Real Estate, Manufacturing, Construction & Property, Other Manufacturing, Webcast, MBC, NYSE, Broadcasting

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced it will release its second quarter 2023 financial results after the market close on Tuesday, August 8, 2023.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced it will release its second quarter 2023 financial results after the market close on Tuesday, August 8, 2023.
  • ET the same day to discuss the financial results and business outlook.
  • The live audio webcast can be accessed on the “Investors” section of the MasterBrand website at www.masterbrand.com .
  • A telephone replay will be available approximately one hour following completion of the call through August 22, 2023.

MEDIA ALERT: WEBINAR: Revolutionizing Mental Health Treatment: Dr. David Clark on the Power of Measurement-Based Care

Retrieved on: 
Tuesday, July 11, 2023
General Health, Health, Mental Health, Other Health, Partnership, University, Psychology, Mental health, Experimental psychology, Health informatics, Thrive, MBC, NHS, IAPT, Nursing, Medical device

Dr. David Clark and his colleagues led the development of the NHS Talking Therapies program (formerly known as IAPT), vastly improving the availability and quality of evidence-based psychological therapies across the UK.

Key Points: 
  • Dr. David Clark and his colleagues led the development of the NHS Talking Therapies program (formerly known as IAPT), vastly improving the availability and quality of evidence-based psychological therapies across the UK.
  • The NHS Talk Therapies program leveraged Measurement-Based Care (consistent outcome measurement) within a stepped-care treatment model to revolutionize the mental health service model within the UK.
  • NHS Talking Therapies has received global recognition for its leadership in setting the standard for evidence-based mental health care and for improving the population’s overall mental health recovery rate.
  • The first event, ‘Revolutionizing Mental Health Treatment: Dr. David Clark on the Power of Measurement-Based Care ’ is now open for registration .

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer

Retrieved on: 
Thursday, July 6, 2023
DNA, Data, Methylation, Doctor of Pharmacy, Breast Cancer Research and Treatment, Progression-free survival, SERD, Demethylation, ESR1, Neoplasm, Breast, Cancer, Fulvestrant, NKT, Mutation, DRS, Prostate, Biomarker, RNA, Radiation therapy, Doctor of Philosophy, Chinese, Associate, Assistant, Harvard Medical School, HR, CTC, Endocrine therapy resistance in breast cancer, Publication, Patient, MBC, Breast cancer, Prostate cancer, Triple-negative breast cancer, DOI, Biology, Hospital, Research, MPH, Massachusetts General Hospital, Metastasis, Pharmaceutical industry, Medical imaging, Vaccine, MD, Cell, Treatment, Medicine

BEVERLY, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx System, announces two publications that demonstrate the utility of CTC molecular analyses in patients with prostate cancer or advanced breast cancer. The papers entitled, “DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells,” and “Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells” were published in Cell (DOI: 10.1016/j.cell.2023.05.028) and Breast Cancer Research and Treatment (DOI: 10.1007/s10549-023-06998-w), respectively. 

Key Points: 
  • “These publications continue to highlight the potential utility of the TellDx technology in a spectrum of clinical settings ranging from early localized disease to advanced metastatic disease.
  • Prostate cancer generally evolves slowly from an indolent low-grade localized condition to poorly differentiated tumor with high likelihood of aggressive metastatic CTCs associated with poor prognosis.
  • Among patients with localized prostate cancer, less than 15% of the cancers are detectable with short circulating tumor DNA hypermethylation assays.
  • Age-matched healthy donors showed minimal signal whereas patients with localized prostate cancer or metastatic prostate cancer revealed a significant DNA hypomethylation signal.

Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients

Retrieved on: 
Wednesday, July 5, 2023
Therapy, MBC, Bristol Myers Squibb, Biomarker, CBR, Messenger, Patient, CDX, ORR, Protocol, Pharmaceutical industry, Medical imaging, European, Drew Allar

Researchers prescreened mBC patients using Allarity’s DRP®-IXEMPRA® CDx, a complex transcriptomic signature comprising multiple mRNA biomarkers of drug response/resistance.

Key Points: 
  • Researchers prescreened mBC patients using Allarity’s DRP®-IXEMPRA® CDx, a complex transcriptomic signature comprising multiple mRNA biomarkers of drug response/resistance.
  • Patients were assigned a DRP®-score, and those with scores above 67% were selected for treatment with IXEMPRA®.
  • Of the 36 patients screened with the DRP®-IXEMPRA® CDx, investigators identified five DRP® positive patients.
  • Among the evaluable patients assessed up to the data evaluation cut-off, there were promising signs of clinical benefit in four out of four evaluable cases:
    One patient experienced 24 weeks of stable disease.

MasterBrand Releases Inaugural Environmental, Social and Governance (ESG) Report

Retrieved on: 
Thursday, June 29, 2023
Residential Building & Real Estate, Manufacturing, Construction & Property, Professional Services, Building Systems, Environmental, Social and Governance (ESG), Other Manufacturing, Retail, Environment, Home Goods, Sustainability, National Forest Foundation, OSHA, Recreation, Beauty, Work, MBC, Biophysical environment, Separate, ESG, Social, POC, NYSE, Female, Video game, Management

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today released the Company’s inaugural Environmental, Social and Governance (ESG) Report.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today released the Company’s inaugural Environmental, Social and Governance (ESG) Report.
  • The report provides an overview of MasterBrand’s ESG progress in many areas and showcases the ways the Company is living its mission to be a responsible steward of resources.
  • “Being a leader in our industry comes with an even greater responsibility to do what is right for all stakeholders, including customers, shareholders, dealers, supply chain partners, our team members and the communities in which we live and work,” said Dave Banyard, President and Chief Executive Officer.
  • “We look forward to the opportunity to further advance our ESG efforts and leave a legacy of positive contributions to our industry and those who enjoy the beauty and functionality of our products.”